Vertex announces positive results from open-label phase 3 study of KALYDECO(R) (ivacaftor)
Vertex announced positive results from an open-label Phase 3 study of KALYDECO® (ivacaftor) in children with cystic fibrosis ages 1 to 2 years who have one of 10 mutations in the cystic fibrosis transmembrane conductance regulator gene. The ARRIVAL study met its primary endpoint of safety. December 07, 2017